Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
Results from Single Classroom-Style Trial Met Pre-Specified Primary and Secondary Endpoints Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 8:00 a.m. ET CORALVILLE, Iowa , July 09, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Intravenous Human Abuse Potential Trial with KP415 Prodrug (KP415.A03) Clinical Findings Intravenous Human Abuse Potential Trial with KP415 Prodrug (KP415.A03) Clinical Findings: Following intravenous
Toggle Summary KemPharm, Inc. to Report First Quarter 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  May 10, 2018 , 4:30 p.m. ET CORALVILLE, Iowa , May 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today
Toggle Summary KemPharm Reports Fourth Quarter and Year End 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: FDA Approval Announced of APADAZ™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain on February 23, 2018 Initiated Pivotal Efficacy
Toggle Summary KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  March 29th, 2018 , 4:30 p.m. ET CORALVILLE, Iowa , March 21, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,
Toggle Summary KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD
Results Suggest that Data from Single Classroom-style Efficacy Study May Be Applicable Across Pediatric, Adolescent and Adult ADHD Patient Populations CORALVILLE, Iowa , March 20, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and
Toggle Summary KemPharm to Present at Upcoming Investor Conferences
Presentations to Highlight Corporate and Clinical Progress CORALVILLE, Iowa , March 06, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive
Toggle Summary KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain
Apadaz is the First Prodrug of Hydrocodone/Acetaminophen to be Approved by FDA Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 2:30 p.m. ET CORALVILLE, Iowa , Feb. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company
Toggle Summary KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Corporate Updates and Clinical Progress to be Highlighted CORALVILLE, Iowa , Feb. 13, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the Company’s
Toggle Summary KemPharm to Present at The MoneyShow Orlando Investor Conference
CORALVILLE, Iowa , Jan. 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C.
Toggle Summary KemPharm Receives Patent Grant for KP606, a Prodrug of Oxycodone
Additional Patent Granted for the KP511-related family, a Prodrug of Hydromorphone CORALVILLE, Iowa , Jan. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today
Toggle Summary KemPharm Initiates Pivotal Efficacy Trial of KP415
‘Classroom-style’ Pivotal Efficacy Trial of ADHD Prodrug Composition Candidate  to Study Onset and Duration of Efficacy and Product Safety Screening commenced in November; first patient treatment occurred December 20, 2017 CORALVILLE, Iowa , Jan. 08, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate,  Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End CORALVILLE, Iowa , Nov. 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company
Toggle Summary KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Filed IND for KP484, A Super-Extended Release ADHD Methylphenidate Prodrug Product Candidate --  KP484 IND Review Completed by FDA ; Cleared to Proceed to Clinical
Toggle Summary KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511
Asalhydromorphone’s Physicochemical and Pharmacological Attributes May Offer the Potential to Provide Significant Pain Relief with the Potential of Reduced Opioid Abuse and Misuse CORALVILLE, Iowa , Nov. 06, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc , a clinical-stage specialty pharmaceutical company
Toggle Summary KemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies
KP484 Designed to be a Predictably Dosed, “ Super-Extended” Release, Methylphenidate Product Candidate CORALVILLE, Iowa , Nov. 02, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc , a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced
Toggle Summary KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD
Agreement May Lead to Addition of New Drug Product Candidate and Indication to KemPharm’s Prodrug Development Pipeline CORALVILLE, Iowa , Oct. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate
KP484 Designed to be a Predictably Dosed, Super-Extended Release, Methylphenidate Product CORALVILLE, Iowa , Sept. 20, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, 
Toggle Summary KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
FDA Has Assigned a PDUFA Action Date of February 23, 2018 Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa , Sept. 12, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm, Inc. Reports Second Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights : KP415.109 Pharmacokinetics Phase 1 Trial Completed Held KP415 End-of-Phase 1 Meeting with U.S. Food and Drug Administration ( FDA ) Initiated